phase 2 trial is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-09-26. Numbers and descriptions here follow the published literature rather than marketing material.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
The cover for the latter song included a musical sequence in the episode where it was featured, depicting Kimiko and Frenchie dancing and singing together across hospital, though it was not featured in the soundtrack in contrast to the former song which was briefly depicted in the premiere episode where Kimiko starts to sing after seeing a woman play the piano. A soundtrack album for the season was released digitally by Madison Gate Records on July 8, 2022.
=== Retinol esters have been used as markers === Retinyl esters can be distinguished from retinol in serum and other tissues and quantified with the use of methods such as high-performance liquid chromatography. Elevated amounts of retinyl ester (i.e., >10% of total circulating vitamin A) in the fasting state have been used as markers for chronic hypervitaminosis A in humans and monkeys. This increased retinyl ester may be due to decreased hepatic uptake of vitamin A and the leaking of esters into the bloodstream from saturated hepatic stellate cells.
== External links == "Viral Haemorrhagic Fever". The National Archives of United Kingdom. Public Health England (PHE). Archived from the original on 2014-07-14. "Viral Haemorrhagic Fevers". World Health Organization (WHO). United Nations (UN). Archived from the original on August 23, 2004. "Viral Hemorrhagic Fevers (VHFs) Virus Families". National Center for Emerging and Zoonotic Infectious Diseases (NCEZID). U.S. Centers for Disease Control and Prevention (CDC). 2019-09-24.
Although the party's ideology has shifted throughout its existence, it has consistently presented itself through a Christian democratic and politically Catholic profile. It was seen to occupy the political centre, although the party is considered to have shifted towards the right of centre in early 1930s under the leadership of Ludwig Kaas. The Oxford Handbook of the Weimar Republic argues that while "Until recently, historians considered Kaas to have been an... ominous indication of the Centre’s shift to the right", the party's position was "more nuanced", as it continued to accept the legitimacy of the Weimar Republic and its constitution, and Kaas strove to reconcile both the left-leaning and right-leaning wings of the party. The party adopted a new program in 2008 in which it stated rejection for the traditional left and right divide of politics and called for a "value-oriented" platform guided by the principles of Christianity and Basic Law for the Federal Republic of Germany. The party supports the traditional family unit and is generally opposed to abortion. It has given support to right to life movements in Germany. During the Weimar era, the Centre Party was socially and economically heterogenous and included groups of various political views and interests, including republicans and monarchists. It represented the entire "political microcosm of Weimar Catholic society".
Sources: en.wikipedia.org
Amphetamine exerts its behavioral effects by altering the use of monoamines as neuronal signals in the brain, primarily in catecholamine neurons in the reward and executive function pathways of the brain. The concentrations of the main neurotransmitters involved in reward circuitry and executive functioning, dopamine and norepinephrine, increase dramatically in a dose-dependent manner by amphetamine because of its effects on monoamine transporters. The reinforcing and motivational salience-promoting effects of amphetamine are due mostly to enhanced dopaminergic activity in the mesolimbic pathway. The euphoric and locomotor-stimulating effects of amphetamine are dependent upon the magnitude and speed by which it increases synaptic dopamine and norepinephrine concentrations in the striatum. Amphetamine potentiates monoaminergic neurotransmission primarily by entering axon terminals either through active transport by monoamine transporters (DAT, NET, and SERT) or by passive diffusion across neuronal membranes. The uptake of amphetamine through these transporters produces competitive reuptake inhibition, since amphetamine competes with endogenous monoamines for transporter-mediated clearance from the synaptic cleft. Once inside the neuronal cytosol, amphetamine can interact with its receptor protein targets to initiate signaling cascades that activate intracellular effectors which regulate monoamine transporter function and surface expression at the plasma membrane.
=== all-α === All-α proteins are a class of structural domains in which the secondary structure is composed entirely of α-helices, with the possible exception of a few isolated β-sheets on the periphery. Common examples include the bromodomain, the globin fold and the homeobox.
== Illicit production == Illicit production and sale of etonitazene has been limited. Identified on the Moscow illegal drug market in 1998, it was primarily smoked in laced cigarettes. A chemist at Morton Thiokol synthesized the compound for his own use. The drug was produced in Russia in 1996 and sold as 'Chinese Dwarf'. The drug resulted in an unconfirmed number of deaths due to its uncertain potency. Etonitazene appears to have a steep dose-response curve, and unpredictable pharmacokinetics especially when injected, in a similar manner to some other potent opioids such as dextromoramide, which may cause etonitazene to be especially hazardous when compared to opioids of similar potency such as fentanyl.
== Uses == In the pharmaceutical industry, shikimic acid from the Chinese star anise (Illicium verum) is used as a base material for production of oseltamivir (Tamiflu). Although shikimic acid is present in most autotrophic organisms, it is a biosynthetic intermediate and in general found in very low concentrations. The low isolation yield of shikimic acid from the Chinese star anise is blamed for the 2005 shortage of oseltamivir. Shikimic acid can also be extracted from the seeds of the sweetgum (Liquidambar styraciflua) fruit, which is abundant in North America, in yields of around 1.5%. For example, 4 kg (8.8 lb) of sweetgum seeds is needed for fourteen packages of Tamiflu. By comparison, star anise has been reported to yield 3% to 7% shikimic acid. Biosynthetic pathways in E. coli have recently been enhanced to allow the organism to accumulate enough material to be used commercially. A 2010 study released by the University of Maine showed that shikimic acid can also be readily harvested from the needles of several species of pine tree. Protecting groups are more commonly used in small-scale laboratory work and initial development than in industrial production processes because their use adds additional steps and material costs to the process. However, the availability of a cheap chiral building block can overcome these additional costs, for example, shikimic acid for oseltamivir. Aminoshikimic acid is also an alternative to shikimic acid as a starting material for the synthesis of oseltamivir.
Grades from four quarters of 7th grade and the first quarter of 8th grade (or four quarters of 8th grade and first quarter of 9th grade) in math, science, English, and social studies A standardized reading comprehension test A standardized numerical test All of these are factored into a final score. The number of students admitted into the S/T program vary from each school, but as an example, 225-250 students with the top scores are admitted to Roosevelt's Science and Technology Program. The next 60 students are placed on a waiting list. All interested 8th and 9th grade students who are residents of Prince George's County are eligible to apply for admission to the Science and Technology Center.
Sources: en.wikipedia.org
== Advertising == In late 1986, Domino's was well known for its advertisements featuring a slapstick character called the Noid, created by Group 243 Inc. who hired Will Vinton Studios to produce the television commercials that featured the character. The character was designed to be the personification of any and all possible unsatisfactory experiences when having pizza delivered; as such, the catchphrase associated with the commercials was "Avoid the Noid". The ad campaign gained notoriety, however, in 1989, when a man named Kenneth Lamar Noid, believing the mascot to be an imitation of him, held two Domino's employees hostage in Chamblee, Georgia. The employees escaped while Noid ate a pizza he had ordered. Noid was eventually diagnosed with paranoid schizophrenia and acquitted due to insanity, and later committed suicide in 1995. Contrary to popular belief, Domino's has stated that the retirement of the Noid ad campaign was not a result of the hostage situation. The Noid was briefly brought back for a week in 2011 in an arcade-style game on the Domino's Facebook page. The person with the top score received a coupon for a free pizza. Owing to a glitch on the Domino's website, the company gave away nearly 11,000 free medium pizzas in March 2009. The company had planned the campaign for December 2008 but scrapped the idea and never promoted it.
=== Diabetes mellitus === Diabetes mellitus (DM) is an immune-disease characterized by the presence of hyperglycemia. Typically these symptoms are brought about by insulin deficiency. However, there have been many recent articles alluding to a correlation between hsp70, in some cases hsp60, and DM. Another recent article discovered the ratio of ehsp70 and ihsp70 could have an effect on DM, leading to a sufficient biomarker. Serum levels of hsp70 have also been shown to increase over time in patients with diabetes.
There is a high amount of glutamate in mammalian cells. Glutamate is necessary for excitatory signaling between neurons. The release must be highly organized, due to the large amounts of glutamate at the synaptic cleft, and the fact that it is released at high speeds. This mechanism of release at the synaptic cleft is partially controlled through the active transport of glutamate out of astrocytes by system Xc-. This release also has a physiological role in the regulation of glutamatergic metabotropic receptors and control of other neurotransmitters. It has been demonstrated that, in the embryonic retina, Xc- exchanger is responsible for 50% of total glutamate uptake, representing a Sodium-Independent system within this tissue. The high activity of Xc- in the retina is correlated to a neuroprotective role, once it can take up excessive extracellular glutamate and provide precursors for the synthesis of Glutathione.
After the reforms ended in 1909, the Indian Army was organised along British lines, although it was always behind in terms of equipment. An Indian Army division consisted of three brigades each of four battalions. Three of these battalions were of the Indian Army, and one British. The Indian battalions were often segregated, with companies of different tribes, castes or religions. One and a half million volunteers came forward from the estimated population of 315 million in the Indian subcontinent. Regimental battalions were not permanently allocated to particular divisions or brigades, but instead spent some years in one formation, and were then posted to another elsewhere. This rotating arrangement was intended both to provide all units with experience of active service on the Frontier, and to prevent them becoming 'localised' in static regimental stations. In contrast, the divisional locations remained constant.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.